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Abstract
INTRODUCTION: Data on HIV treatment outcomes in people who inject drugs (PWID) in the Asia-Pacific are sparse despite
the high burden of drug use. We assessed immunological and virological responses, AIDS-defining events and mortality among
PWID receiving antiretroviral therapy (ART).
METHODS: We investigated HIV treatment outcomes among people who acquired HIV via injecting drug use in the TREAT
Asia HIV Observational Database (TAHOD) between January 2003 and March 2019. Trends in CD4 count and viral suppres-
sion (VS, HIV viral load <1000 copies/mL) were assessed. Factors associated with mean CD4 changes were analysed using
repeated measures linear regression, and combined AIDS event and mortality were analysed using survival analysis.
RESULTS: Of 622 PWID from 12 countries in the Asia-Pacific, 93% were male and the median age at ART initiation was
31 years (IQR, 28 to 34). The median pre-ART CD4 count was 71 cells/µL. CD4 counts increased over time, with a mean dif-
ference of 401 (95% CI, 372 to 457) cells/µL at year-10 (n = 78). Higher follow-up HIV viral load and pre-ART CD4 counts
were associated with smaller increases in CD4 counts. Among 361 PWID with ≥1 viral load after six months on ART, propor-
tions with VS were 82%, 88% and 93% at 2-, 5- and 10-years following ART initiation. There were 52 new AIDS-defining
events and 50 deaths during 3347 person-years of follow-up (PYS) (incidence 3.05/100 PYS, 95% CI, 2.51 to 3.70). Previous
AIDS or TB diagnosis, lower current CD4 count and adherence <95% were associated with combined new AIDS-defining
event and death.
CONCLUSIONS: Despite improved outcomes over time, our findings highlight the need for rapid ART initiation and adher-
ence support among PWID within Asian settings.
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1 | INTRODUCTION
Globally, injecting drug use is a major public health concern
leading to substantial health burden and transmission risk of
blood-borne infections from injecting equipment sharing beha-
viours. In a multi-stage systematic review, it was estimated
that there were nearly 4 million people who inject drugs
(PWID) reside within the east and southeast Asia, with a pop-
ulation prevalence of 0.25% (95% confidence interval [CI],
0.19 to 0.31) [1]. Among the PWID population in the region,
HIV and hepatitis C infections occur in 15% and 50% respec-
tively [1].
The HIV cascade of care is a useful framework to monitor
people living with HIV (PLHIV) from the first point of diagnosis
to the ultimate goal of achieving high levels of HIV RNA-1 viral
load suppression [2]. Between these steps, linkage to HIV care,
and initiation and adherence to antiretroviral therapy (ART) con-
stitute the overall framework of the HIV care cascade towards
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attaining successful treatment, in which HIV transmission rates
are reduced and disease progression is stalled. Although com-
bined antiretroviral therapy (ART) has benefited millions of
PLHIV and has reduced HIV-associated mortality, studies have
shown that PWID with HIV are at risk for poorer ART adher-
ence [3,4] and poorer virological and immunological responses
to ART compared to the non-injecting individuals [5-7].
The causes of suboptimal treatment outcomes and mortali-
ties are likely multifactorial, including adherence problem [8,9],
opportunistic infections (such as tuberculosis infection)
[10,11], other comorbid conditions (such as hepatitis C virus
co-infection) [1], lack of social support and stigmatization [12].
A number of studies have also found significant links between
poor treatment outcomes among PWID and a range of risk
factors embedded within the social and structural environ-
ments including low socioeconomic status, unstable housing
and incarceration [12]. More importantly, environmental expo-
sures and social barriers such as lack of facilities and support
to access sterile injection equipment, barriers to access
healthcare services, and the criminalization and stigmatization
of drug use have a significant impact on the HIV disease pro-
gression in this hard-to-reach population [13].
Despite the need to identify and target key interventions,
little is known regarding HIV-related treatment outcomes
among HIV-positive PWID living in the Asia-Pacific region. The
few studies that previously evaluated treatment outcomes
among PWID in the region were cross-sectional and had a
short duration of follow-up [14-17]. In this study, we capital-
ized on access to long-term ART follow-up data of TREAT Asia
HIV Observational Database (TAHOD) and aimed to assess
the immunological and virological responses, AIDS-defining
events, and mortality exclusively among PWID receiving ART
in the Asia-Pacific region using data from TAHOD.
2 | MATERIALS AND METHODS
2.1 | Study design and population
This study is a longitudinal analysis evaluating HIV treatment
outcomes among HIV-positive PWID who have started ART.
PLHIV who reported injecting drug use at enrolment as their
primary mode of HIV acquisition in the TAHOD cohort
between January 2003 and March 2019 were included.
TAHOD is a multi-site observational cohort study which
includes 21 participating sites from 12 countries in the Asia-
Pacific region. Details of the cohort and its methods have
been reported in previous studies [18-20]. Briefly, since 2003,
TAHOD selectively enrolled PLHIV aged ≥18 years or older
[18], who were more likely to remain in care. Patients were
followed according to the local standard of care. As of March
2019, the TAHOD cohort included just over 9800 participants
with an average follow-up frequency of 3.83 per 1 person-
year and a median follow-up time of 7.8 years (interquartile
range [IQR], 4.6 to 11.2). TAHOD is entirely observational,
and any tests or interventions are performed according to the
site’s local practices.
2.2 | Study outcomes and covariates
The first part of the study was to evaluate immunological and
virological responses up to 10 years after ART initiation.
Immunological and virological responses were measured by
CD4 changes and the proportion of individuals with HIV viral
suppression after ART initiation respectively. To measure
immunological changes, we included patients with available
baseline CD4 counts, defined as the latest pre-ART CD4
count within six months of treatment initiation. Viral suppres-
sion (VS) was defined as HIV-1 RNA <1000 copies/mL. As a
sensitivity analysis, the threshold of 400 copies/mL was used
to define VS.
The second part of the study was to explore a combined
endpoint of AIDS-defining events and all-cause mortality and
incidence of TB. AIDS-defining events were defined as having
a condition from the modified CDC AIDS-indicator list, includ-
ing tuberculosis (TB) or an AIDS-related cancer. All-cause mor-
tality was defined as AIDS- and non-AIDS-related deaths.
Causes of death were based on the review of the standard-
ized Cause of Death (CoDe) form outlined by the D:A:D study
[21]. Participants who had an AIDS event and died were
counted as dead due to AIDS event. TB was defined as having
either presumptive or definitive pulmonary, or extrapulmonary
TB disease.
We considered a range of sociodemographic variables,
including age (≤30, 31 to 40, 41 to 50 and ≥51 years), sex,
and country income level (low-middle and high income). Self-
reported adherence was collected during follow-up visits from
the visual analogue scale [3]. Additionally, treatment and
clinical-related variables were considered and modelled as
time-fixed covariates, including hepatitis B and C co-infection,
prior AIDS diagnosis or TB diagnosis preceding ART initiation,
year of treatment initiation (≤ 2002, 2003 to 2007, 2008 to
2012 and 2013 to 2018). Hepatitis B (HBV) and C (HCV) co-
infections were defined as having an ever-positive result of
hepatitis B surface antigen and HCV antibody respectively.
Time-varying covariates included in the study were age, CD4
count, HIV-1 RNA level, ART regimen (Non-nucleoside reverse
transcriptase inhibitor (NNRTI)-based, and protease inhibitor
(PI)-based), body mass index (BMI) and self-reported ART
adherence (≤95% vs. >95%). Loss-to-follow-up (LTFU) was
defined as having no visit for at least 12 months prior to the
data transfer date.
2.3 | Statistical analysis
Participants with at least one CD4 measurement after six
months on ART were included in the CD4 outcome analysis.
Factors associated with CD4 changes up to 10 years from
ART initiation were evaluated using repeated measure linear
regression (generalized estimating equation (GEE) with
exchangeable correlation matrix using robust covariance esti-
mation), adjusting for site and time on ART. The proportion of
patients with VL suppression was analysed descriptively. Par-
ticipants with at least one viral load measurement after six
months on ART were included.
Risk factors for TB, and combined AIDS-defining event and
death were evaluated by Cox proportional hazard models.
Crude incidence rates of combined AIDS/death and new TB
events were reported per 100 persons years (/100 PYS). TB
incident cases were analysed as a separate outcome and also
included in the AIDS events/death analysis.
Survival time was left truncated at ART initiation or cohort
entry, whichever occurred last, and ended on the outcome of
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interest. Patients who did not experience the outcome were
lost to follow-up, or transferred out were censored on their
last visit date. Covariates from the univariable analysis with
p < 0.10 were fitted in the multivariable models using a back-
ward stepwise selection process. Covariates with p < 0.05 in
the multivariable models were considered significant. Given
the potential disparities in healthcare systems across the sites,
analyses were stratified by site. As a sensitivity analysis, fac-
tors associated with CD4 changes over time were also anal-
ysed using linear mixed effect models with a random intercept
on patients. All analyses were performed using SAS software
version 9.4 (SAS Institute Inc., Cary, NC, USA) and STATA
software version 14.2 (STATA Corp., College Station, TX,
USA).
2.4 | Ethical considerations
Ethics approvals were obtained from respective local ethics
committees of all TAHOD-participating sites, the Kirby Insti-
tute (data management and statistical analysis centre) and
TREAT Asia/amfAR (coordinating centre). Informed consent
was waived unless specified by the local institutional review
board at each participating site.
3 | RESULTS
3.1 | Participant characteristics
Among 8622 participants with known first ART start date
enrolled in the cohort until March 2019, 622 PWID (7.2%)
were identified (Figure 1), of which 578 (93%) were male, and
510 (82%) were from low-middle income countries. The par-
ticipants included were from China (n = 9), Hong Kong SAR
(n = 6), India (n = 2), Indonesia (n = 316), Malaysia (n = 51),
the Philippines (n = 1), Singapore (n = 2), Taiwan (n = 9), Thai-
land (n = 35) and Vietnam (n = 191). The median age at ART
initiation was 31 years (IQR, 28 to 34). The prevalence of
HBV and HCV co-infection was 10% and 71% respectively.
Among PWID participants, 52 (8%) were co-infected with
both HBV and HCV. Over half (54%) had a history of an AIDS
diagnosis, and over one-third (34%) had been diagnosed with
TB. Most (97%) started HIV treatment with non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based ART regimen,
and the majority (59%) started ART in the 2005 to 2010 per-
iod. The median follow-up time of our study group was
7.7 years (IQR, 3.8 to 10) with an average follow-up rate of
4.89 (95% CI, 4.82 to 4.97) per 1 person-year. Table 1
describes the characteristics of PWID participants in greater
detail.
3.2 | Immunological and virological responses after
ART initiation over time
The median pre-ART CD4 was 72 (IQR, 55 to 88) cells/µL
among 435 PWID (70%) who had a CD4 count available before
ART initiation. An overall increase in CD4 was observed up to
10 years after ART initiation (Figure 2A). Among 76 PWID who
were followed up at 10 years after ART initiation and had CD4
results available, there was a mean CD4 increase of 401 cells/
uL (95% CI, 372 to 457) at the 10th year of follow-up
(Figure 2C). Figure 2B and D show the median CD4 count and
median CD4 change by initial CD4 count (≤50, 51 to 100, 101
to 200 and >200 cells/µL). Although PWID with different base-
line CD4 counts showed increasing trends of CD4 during their
follow-up, only those with baseline CD4 >200 had achieved
CD4 recovery of >500 since ART initiation.
Figure 1. Participant inclusion flowchart.
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Characteristics associated with mean CD4 changes over
time in the multivariate analysis were current HIV viral load
401 to 100,000 copies/mL (difference = 65.3 cells/µL, 95%
CI, 106.8 to 23.8, p = 0.002) and >100,000 copies/mL
(120.7, 95% CI, 174.8 to 66.7, p < 0.001) compared with
viral load ≤400 copies/mL, pre-ART CD4 51 to 100 cells/µL
(45.6, 95% CI, 79.8 to 11.4, p = 0.01), 101 to 200 cells/µL
(69.3 cells/µL, 95% CI, 103.7 to 34.8, p < 0.001) and




N = 622 (100%)
Yes
N = 102 (16.4%)
No
N = 520 (83.6%)
Yes
N = 35 (5.6%)
No
N = 587 (94.4%)
Sex
Male 578 (92.9%) 96 (94.1%) 482 (92.7%) 33 (94.3%) 545 (92.8%)
Female 44 (7.1%) 6 (5.9%) 38 (7.3%) 2 (5.7%) 42 (7.2%)
Age at ART initiation
≤30 303 (48.7%) 46 (45.1%) 257 (49.4%) 12 (34.3%) 291 (49.6%)
31 to 40 271 (43.6%) 39 (38.2%) 232 (44.6%) 20 (57.1%) 251 (42.8%)
41 to 50 44 (7.1%) 16 (15.7%) 28 (5.4%) 3 (8.6%) 41 (7%)
51+ 4 (0.6%) 1 (1%) 3 (0.6%) 0 (0%) 4 (0.8%)
Initial ART regimen
NRTI+NNRTI 603 (97%) 97 (95.1%) 506 (97.3%) 34 (97%) 569 (96.9%)
NRTI+PI 19 (3%) 5 (4.9%) 14 (2.7%) 1 (3%) 18 (3.1%)
HBV coinfection
Negative 434 (69.8%) 69 (67.6%) 365 (70.2%) 23 (65.7%) 411 (70%)
Positive 64 (10.3%) 11 (10.8%) 53 (10.2%) 3 (8.6%) 61 (10%)
Not tested 124 (19.9%) 22 (21.6%) 102 (19.6%) 9 (25.7%) 115 (20%)
HCV coinfection
Negative 81 (13%) 12 (11.8%) 69 (13.3%) 4 (11.4%) 77 (13.1%)
Positive 440 (70.7%) 69 (67.7%) 371 (71.3%) 22 (62.9%) 418 (71.2%)
Not tested 101 (16.2%) 21 (20.6%) 80 (15.4%) 9 (25.7%) 92 (15.7%)
History of AIDS diagnosis
No 287 (46%) 28 (27.4%) 259 (49.8%) 10 (28.6%) 397 (67.6%)
Yes 335 (54%) 74 (72.6%) 261 (50.2%) 25 (71.4%) 190 (32.4%)
History of tuberculosis
No 413 (66.4%) 56 (54.9%) 357 (68.6%) 16 (45.7%) 357 (68.7%)
Yes 209 (33.6%) 46 (45.1%) 163 (31.4%) 19 (54.3%) 163 (31.3%)
Ever smoke
No 45 (7.2%) 9 (8.8%) 36 (7%) 2 (5.7%) 43 (7.3%)
Yes 420 (67.5%) 55 (53.9%) 365 (70%) 24 (68.6%) 396 (67.5%)
Not reported 157 (25.2%) 38 (37.2%) 119 (23%) 9 (25.7%) 148 (25.2%)
Year of ART initiation
<2005 97 (15.6%) 27 (26.3%) 70 (13.5%) 11 (31.4%) 86 (14.6%)
2005 to 2010 366 (58.8%) 55 (53.9%) 311 (59.8%) 21 (60.0%) 345 (58.8%)
>2010 159 (25.6%) 20 (19.6%) 139 (26.7%) 3 (8.6%) 156 (26.6%)
Country income level
Low-middle income countries 510 (82%) 77 (75.5%) 433 (83.3%) 25 (71.4%) 485 (82.6%)
High income countries 112 (18%) 25 (24.5%) 87 (16.7%) 10 (28.6%) 102 (17.4%)
Pre-ART CD4+ count (cells/µL)
≤50 199 (32%) 43 (42.2%) 156 (30%) 10 (28.6%) 189 (32.2%)
51 to 100 79 (12.7%) 13 (12.7%) 66 (12.7%) 2 (5.7%) 77 (13.1%)
101 to 200 100 (16.1%) 14 (13.7%) 86 (16.5%) 6 (17.1%) 94 (16%)
>200 80 (12.9%) 10 (9.8%) 70 (13.5%) 4 (11.4%) 76 (13%)
Not done 164 (26.3%) 22 (21.6%) 142 (27.3%) 13 (37.1%) 151 (25.7%)
ART, antiretroviral therapy; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcrip-
tase inhibitor; PI, protease inhibitor.
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>200 cells/µL (97.1, 95% CI, 145.4 to 48.8, p < 0.001)
compared with CD4 ≤50 cells/µL. The adherence variable was
not included in the analysis of CD4 changes due to multi-
collinearity with HIV viral load (variance inflation factor,
VIF = 14.3). We did not find an association with past AIDS or
TB diagnosis, age at ART initiation, year of ART initiation, ini-
tial ART regimen and time-updated BMI (Table 2). In the sen-
sitivity analysis where we applied a linear mixed effect model
with random effects on patients (Table S2), the estimates of
the effects were similar to the estimates from the GEE model
with an exchangeable correlation matrix.
Among 361 PWID with at least one viral load measurement
after six months on ART, the proportion with VS changed
from 83% (120/145) in the first year of ART initiation, to 82%
(115/140), 88% (82/93) and 93% (63/68) at 3, 5 and
10 years after starting of ART. In a sensitivity analysis when
the threshold was used as 400 copies/mL, the proportion of
VS remained the same as 1000 copies/mL. The proportion of
VS over different years of ART initiation was comparable:
85%, 87% and 88% during years of <2005, 2005 to 2010 and
>2010 respectively. In addition, 12 of the 25 PWID who did
not have HIV VS at year 1 (48%) had died or LTFU by year
10, compared to 47 of 115 PWID who had VS (41%).
3.3 | Incidence of AIDS/death events and TB
among PWID
During 3347 PYS of follow-up, there were 52 AIDS events
and 50 deaths with a combined incidence rate of 3.05 (95%
CI, 2.51 to 3.70)/100 PYS (Figure 3). Twenty-five PWID died
due to AIDS-related events, with 17 deaths occurred due to
non-AIDS events and 8 of unknown causes. The median
follow-up time from six months after ART to the date of
AIDS-event or death was 4.5 years (IQR 2.4 to 7). Nearly
30% of non-AIDS mortality were due to liver-related mortality.
In the multivariate analysis, previous AIDS diagnosis
(HR = 1.86, 95% CI, 1.16 to 3.01, p = 0.01), current CD4 ≤50
cells/µL (HR = 5.79, 95% CI 2.99 to 11.25, p < 0.001) and
CD4 of 51 to 100 cells/µL (HR = 3.39, 95% CI 1.59 to 7.19,
p = 0.001) and ART adherence of ≤95% (HR = 11.1, 95% CI,
3.22 to 37.73, p < 0.001) were associated with incidence of
new AIDS event or death (Table 3).
There were 35 new TB cases among 622 PWID. The inci-
dence rate for TB was 1.01 (95% CI, 0.73 to 1.41)/100 PYS.
Past TB diagnosis (HR = 2.69, 95% CI 1.23 to 5.87,
p = 0.013), current age (>30 years, HR = 3.40, 95% CI, 1.24
to 9.34, p = 0.017; vs. ≤30 years), ART adherence ≤95%
Figure 2. Longitudinal CD4 changes after ART initiation. A total of 435 people who inject drugs (PWID) contributed to pre-ART CD4 count
at baseline. Among them, 186 PWID had CD4 count ≤50 cells/µL, 77 had CD4 count 51 to 100 cells/µL, 96 had CD4 count 101 to 200
cells/µL and 76 had CD4 count >200 cells/µL at baseline respectively. (A and C) show overall median (95% CI) absolute CD4 count and median
(95% CI) CD4 change from baseline respectively. (B and D) show median absolute CD4 count and median CD4 change from baseline with differ-
ent pre-ART CD4 counts (≤50, 51 to 100, 101 to 200 and >200 cells/µL).
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Table 2. Factors associated with CD4 changes up to10 years after ART initiation
Total 435 PWID participants
Univariable Multivariable
Difference (cells/µL) 95% CI p-value Difference (cells/µL) 95% CI p-value
Time-varying age (years)a
≤30 Ref Ref
>30 8.5 31.5, 14.6 0.473 7.5 30.2, 17.6 0.510
Sex
Male Ref 0.736
Female 11.5 78.4, 55.4 0.168
Year of ART initiation
<2005 Ref
2005 to 2010 31.0 27.4, 89.4 0.297
>2010 18.7 80.4, 43.1 0.554
HIV viral load (copies/mL)a
≤400 Ref Ref <0.001
401 to 100,000 92.5 129.4, 55.6 <0.001 65.3 106.6, 23.9 0.002
>100,000 157.7 223, 92.3 <0.001 121.4 176.0, 66.7 <0.001
Not reported
Pre-ART CD4 (cells/µL)
≤50 Ref <0.001 Ref <0.001
51 to 100 46.6 88.4, 4.8 0.029 45.3 79.5, 11.2 0.009
101 to 200 60 98.7, 21.3 0.002 69.5 104.0, 34.9 <0.001
>200 89.5 132.8, 46.2 <0.001 96.9 145.1, 48.7 <0.001
BMI (kg/m2)a
<25 0.111
≥25 33.4 11.8, 78.5 0.147
Not reported 7.7 23, 7.6 0.322
Adherencea
≤95% Ref
>95% 105.3 53.7, 156.9 <0.001
Not reported
ART regimena
No treatment 11.2 47.5, 182.5 0.554
NRTI + NNRTI Ref
NRTI + PI 81.5 17.8, 201.2 0.185
Other combinations 22.5 83.5, 201.2 0.365
Ever smoke
No Ref








Positive 33.1 80.5, 14.2 0.170
Not tested
History of AIDS diagnosis
No Ref
Yes 8.2 23.1 to 39.5 0.608
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(HR = 24.23, 95% CI 1.62 to 42.19, p = 0.013) and current
CD4 (≤50 cells/µL, HR = 5.53, 95% CI 2.05 to 14.97,
p = 0.001; vs. >200 cells/µL) were associated with TB diagno-
sis (Table S1).
4 | DISCUSSION
This study evaluated longitudinal immunological and virological
outcomes and incidence of AIDS/death and TB among the
TAHOD PWID population. CD4 counts and proportions of
viral suppression continued to increase up to 10 years post-
ART initiation. Lower pre-ART CD4 and lower current HIV
viral load were associated with greater CD4 increase over the
years of follow-up. There were high proportions of HBV and
HCV co-infections among the population. In addition, previous
AIDS diagnosis, lower current CD4 counts and suboptimal
treatment adherence were associated with having an AIDS
event/mortality in our study group.
Our study found that PWID with lower pre-ART CD4 expe-
rienced greater CD4 gains after starting ART, compared to
those with higher pre-ART CD4. The overall rate of change
was faster in the first three years after starting ART. This is
consistent with previous studies which showed a greater CD4
changes in the early years of treatment initiation [22,23]. Fur-
thermore, only those with pre-ART CD4 >200 cells/µL had
their CD4 increase to above 500 cells/µL during follow-up.
Previous reports also suggested that individuals living with
HIV who had higher CD4 at ART initiation predicted better
CD4 recovery over the course of treatment [24,25]. Findings
from our study highlight the importance of addressing PWID
presenting late to care in order to maximize their treatment
response over time [26].
Current HIV viral load was associated with CD4 changes
following ART initiation among PWID. Individuals with HIV VL
≤400 copies/mL during follow-up had greater CD4 gain over
time, compared to those who had a higher viral load. Higher
viral load after ART initiation may be a result of treatment
interruption or non-adherence, which could be caused by a
range of factors including ongoing injecting drug use, incarcer-
ation periods or poor engagement in opioid agonist therapy
[27]. Individuals who started treatment during earlier years
may have started with less effective ART regimens which
potentially lead to slower viral suppression rate and indirectly
affected CD4 changes over time. However, we found calendar
years of treatment initiation were not statistically associated
with CD4 changes over time.
There was a high proportion of VS in the cohort over the
follow-up period and most of our PWID in the study have
started with NNRTI-based ART regimen. However, the propor-
tion of VS did not differ significantly according to year of ART
initiation, which was categorized according to time periods
when treatment guidelines would have been changing. Despite
this, the high proportion of VS during follow-up suggests
PWID have responded well to HIV treatment. This highlights
the importance of having PWID linked to care immediately
after HIV diagnosis under the “Treat All” strategies for the
implications of “Treatment-as-Prevention” as well as to opti-
mize treatment outcomes among the population.
There was also a high prevalence of HBV and HCV co-
infections among our PWID participants. Nearly 30% of
deaths were due to liver-related problems. The burden of
three blood-borne infections (HIV, HBV, and HCV infections)
among the PWID population was estimated to have enormous
health economic impacts at country, regional and even global
level, according to the Global Burden of Disease Study [28].
In our study, we did not find an association with HBV or HCV
and CD4 changes or AIDS events and mortality. Most partici-
pants were from low-middle income countries where uptakes
of HCV treatment are recently being scaled up. In this cohort,
10% of PWID were co-infected with chronic HBV. Currently,
there are tolerable oral agents for HBV treatment (e.g. teno-
fovir); however, the accessibility of those drugs remains low in
resource-limited countries, especially where PWID have
encountered barriers to engagement with the health system
[29]. Therefore, the impact of chronic HCV and HBV infec-
tions on the comorbidities of HIV-positive PWID remains
unclear. Although our study did not include HCV treatment or
liver-related outcomes, future studies and evaluations of these
outcomes are warranted to guide policy makers in the imple-
mentation of intervention strategies among PWID in the
region. Nonetheless, regular, and adequate screening, and
timely treatment of hepatitis infections are critical for PWID
population.
Lower CD4 count was shown to be associated with new
AIDS events or death in our study. Previous studies have sug-
gested poorer treatment outcomes of PWID especially those
with low CD4 count. Our study results are consistent with
Table 2. (Continued)
Total 435 PWID participants
Univariable Multivariable
Difference (cells/µL) 95% CI p-value Difference (cells/µL) 95% CI p-value
History of tuberculosis
No Ref
Yes 4.2 31.1, 39.6 0.814
All model covariates were stratified by site. Global p-values for age and CD4 are tests for trend. All other global p-values are tests for hetero-
geneity excluding missing values. Time from ART initiation was also adjusted in the final model. p-values in bold represent significant covariates in
the final model. ART, antiretroviral therapy; NRTI, nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleotide reverse transcriptase inhibitor;
PI, protease inhibitor; BMI, body mass index.
aAge, HIV viral load, BMI, ART regimen and adherence data are time-varying variables.
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previous studies that demonstrated individuals with current
CD4 counts less than 200 cells/µL having a higher risk for
developing new AIDS events/death after ART initiation [30].
Our study also found that suboptimal drug adherence among
PWID was associated with AIDS events or mortality.
We have evaluated TB as a separate outcome in this study.
PWID tend to be at a greater risk of developing TB and are
more likely to not be retained within the TB treatment pro-
gramme [12]. TB incidence rate in the study was 1.01 (95%
CI, 0.73 to 1.41) per 100 PYS in the cohort. This is
Figure 3. Kaplan–Meier curves for AIDS-defining events/deaths tuberculosis among PWID. A total of 622 people who inject drugs (PWID)
in the study analysis were recruited from 22 sites in Cambodia, China and Hong Kong SAR, India, Indonesia, Japan, Malaysia, the Philippines,
Singapore, South Korea, Taiwan, Thailand and Vietnam. Site-stratified survival graphs for (A) overall combined AIDS-defining events and
deaths, (B) overall tuberculosis, (C) combined AIDS-defining events and deaths and (D) tuberculosis by time updated CD4 counts: ≤50, 51 to 100,
101 to 200 and >200 cells/µL, (E) combined AIDS-defining events and deaths and F) tuberculosis by time-varying CD4 counts: ≤200, 201 to 350,
351 to 500 and >500 cells/µL.
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(/100 pys) 95% CI
Univariable Multivariable
HR 95% CI p-value HR 95% CI p-value
Total 622 3347.73 102 3.05 2.51 to 3.70
Sex
Male 578 3105.48 96 3.09 2.53 to 3.78 Ref
Female 44 242.25 6 2.48 1.11 to 5.51 0.67 0.29 to 1.56 0.356
Time-varying age (years)a
≤30 – 496.72 21 4.23 2.76 to 6.48 Ref 0.121 Ref
>30 – 2825.36 81 2.87 2.31 to 3.56 1.53 0.89 to 2.61 0.605 1.53 0.88 to 2.66 0.128
ART regimena
No treatment – 28.87 3 10.39 3.35 to 32.22 2.07 0.57 to 7.51 0.267
NRTI+NNRTI – 2940.12 85 2.89 2.34 to 3.58 Ref
NRTI+PI – 327.03 10 3.06 1.65 to 5.68 1.09 0.50 to 2.39 0.816
Others – 46.44 4 8.61 3.23 to 22.95 1.74 0.46 to 6.61 0.417
HBV co-infection
Negative 434 2376.97 69 2.9 2.29 to 3.68 Ref
Positive 64 353.38 11 3.11 1.72 to 5.62 1.06 0.54 to 2.06 0.861
Not tested 124 617.39 12 3.56 2.35 to 5.41
HCV co-infection
Negative 81 438.18 12 2.74 1.56 to 4.82 Ref
Positive 440 2436.53 69 2.83 2.24 to 3.59 1.18 0.60 to 2.31 0.631
Not tested 101 473.03 21 4.44 2.89 to 6.81
History of AIDS diagnosis
No 287 1582.52 28 1.77 1.22 to 2.56 Ref Ref
Yes 335 1765.21 74 4.19 3.34 to 5.26 2.13 1.34 to 3.37 0.001 1.86 1.16 to 3.01 0.010
Not reported 300 1169.83 66 5.64 4.43 to 7.18
BMI (kg/m2)a
<25 – 2538.23 77 3.03 2.43 to 3.79 Ref
≥25 – 438.21 9 2.05 1.07 to 3.95 0.59 0.28 to 1.22 0.158
Not reported – 371.29 16 4.31 2.64 to 7.03
Year of ART initiation
<2005 97 677.2 27 3.99 2.73 to 5.81 Ref 0.486
2005 to 2010 366 1939.5 55 2.84 2.18 to 3.69 0.64 0.30 to 1.34 0.236
>2010 159 705.4 20 2.84 1.83 to 4.39 0.68 0.31 to 1.57 0.371
Adherencea
≤95% – 69.26 5 7.22 3.00 to 17.34 17.27 5.12 to 58.24 <0.001 11.1 3.22 to 37.73 <0.001
>95% – 1634.32 14 0.86 0.51 to 1.45 Ref Ref
Not reported – 1644.15 83 5.05 4.07 to 6.26 <0.001 <0.001
CD4+ cell count (cells/µL)a
≤50 – 88.43 28 31.66 21.86 to 45.86 8.56 4.49 to 16.35 <0.001 5.79 2.99 to 11.25 <0.001
51 to 100 – 110.30 15 13.60 8.20 to 22.56 5.08 2.49 to 10.37 <0.001 3.39 1.59 to 7.19 0.001
101 to 200 – 430.36 15 3.49 2.10 to 5.78 1.92 0.99 to 3.71 0.052 1.54 0.79 to 3.00 0.206
>200 – 2534.47 39 1.54 1.12 to 2.11 Ref Ref
Not done – 184.17 5 2.71 1.13 to 6.52
HIV viral load (copies/mL)a
≤400 – 1736.97 29 1.67 1.16 to 2.40 Ref 0.02
401 to 100000 – 324.71 17 5.24 3.25 to 8.42 2.3 1.15 to 4.6 0.019
>100000 – 117.65 22 10.2 5.79 to 17.96 3.1 1.33 to 7.23 0.009
Not done – 1168.41 44 3.77 2.80 to 5.06
p-values in bold represent significant covariates in the final model. Global p-values are test for heterogeneity excluding missing values. Not
reported/not done categories were included in the multivariable analysis, but not displayed in the table.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; NNRTI, non-nucleotide reverse transcriptase inhibitor; NRTI, nucleotide reverse
transcriptase inhibitor; PI, protease inhibitor.
aAge, CD4, HIV viral load, adherence and BMI are time-varying variables.
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remarkably higher than the general population of many Asian
countries participating in the TAHOD cohort [31]. Our study
found that prior TB diagnosis, lower current CD4 and subopti-
mal drug adherence were also associated with being diag-
nosed with a new TB event. This highlights the importance of
routine screening of TB infections and latent TB therapy
among PWID, especially among those with a history of TB
and low CD4 in HIV clinics.
Like other non-PWID participants in the cohort [20,32], the
majority of PWID participants presented late with a high
prevalence of previous AIDS diagnosis. Studies have shown
that PWIDs face different forms of barriers to treatment and
healthcare services due to stigmatization and criminalization
[33-35], which could largely delay HIV diagnosis or treatment
initiation. Healthcare avoidance or HIV testing avoidance
behaviours among PWID were also previously reported in the
region [36-38]. Therefore, increasing awareness of the bene-
fits of early HIV treatment initiation together with other sup-
portive measures such as treatment adherence support [39],
opioid substitution therapy [40] and harm reduction interven-
tion such as needle syringe programmes [41] are needed to
improve treatment outcomes among the population.
This study has several limitations. First, participants were
designated as PWID based on the presumptive HIV mode of
transmission defined at their enrolment in the cohort, and no
data were collected regarding ongoing drug use or utilization
of methadone therapy among our study participants. There-
fore, we could not evaluate the impact of current illicit drug
use on HIV treatment outcomes. The majority of PWID
included in the study started ART in 2005 to 2010, which
potentially limits the generalizability of our findings to the
“treatment for all” period when ART is recommended after
HIV diagnosis regardless of CD4 threshold, and when less
toxic regimens became available. Another limitation is that the
study group consists of a small number of PWID aged older
than 50 years and a small number who were initiated with a
PI-based regimen as first-line ART combination. As such, the
generalizability of our findings to the general PWID is limited.
Finally, we were not able to account for unobserved con-
founders within our cohort.
5 | CONCLUSIONS
There has been improvement in immunological and virological
responses after ART initiation among PWID. Earlier treatment
initiation and implementation of adherence support pro-
grammes could benefit PWID within the region. Also, in the
Asia-Pacific region, routine HBV and HCV screening and treat-
ment for this marginalized population with easy access to
healthcare services are also critical. Policies enhancing HIV
management, adherence support and prevention services tai-
lored for the needs of PWID, and harm reduction services
should be more widely adopted to control the HIV transmis-
sion in this population group.
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